Humira patent expiry (2023)
AbbVie's Humira, the world's best-selling medicine, lost US patent protection in January 2023. A wave of biosimilar versions launched within months, introducing price competition to a drug that had been a top source of US drug spending.
Multiple biosimilar versions reached the US market, cutting prices for patients.
Turned the US into a major biosimilar market and demonstrated the commercial value of biosimilar platforms.
Explains why Fresenius is consolidating its biosimilar platform as patents on major biologics continue to expire.
